Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02489123 · ClinicalTrials.gov registry record · Phase 2
Enzalutamide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
A Phase 2 study, sponsored by University of Washington.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT02489123 is a Phase 2 study that was terminated before completion, run by University of Washington. The registered enrollment target is 8 participants.
The verdict
NCT02489123, a Phase 2 study, was terminated before completion, sponsored by University of Washington.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
This pilot clinical trial studies enzalutamide in treating patients with mantle cell lymphoma that has returned after a period of improvement (relapsed) or has not responded to previous treatment (refractory). Androgens can cause the growth of cancer cells. Antihormone therapy, such as enzalutamide, may lessen the amount of androgen made by the body.
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Enzalutamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2015-08-11 |
| Est. Completion | 2020-06-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02489123
The ClinicalTrials.gov registry entry for NCT02489123 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02489123 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02489123 about?
NCT02489123 is a clinical study titled "Enzalutamide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma". This pilot clinical trial studies enzalutamide in treating patients with mantle cell lymphoma that has returned after a period of improvement (relapsed) or has not responded to previous treatment (refractory). Androgens can cause the growth of cancer cells. Antihormone therapy, such as enzalutamide,...
What is the current status of trial NCT02489123?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2015-08-11. Estimated completion is 2020-06-16.
What interventions are being tested in trial NCT02489123?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Enzalutamide (DRUG).
Who is sponsoring clinical trial NCT02489123?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.